ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

NCAB Subcommittee Works On Drafting Quantitative Risk Assessment Policy

October 1, 1982

New Understanding of drug Resistance Exciting Revolution

September 17, 1982

Cancer Advocacy: Jay Hedlund Resigns As NPCC President

May 14, 1999

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987

Mark Israel To Direct Norris Cotton Center

October 19, 2001

Fisher, NSABP Executive Committee, File Injunction Seeking Herberman’s Removal

August 12, 1994